Buy BLRX by Jun 8, 2026.

I’d imagine most of you have never heard of $BLRX, but this week can put it on a lot of retail’s radar. First patient just dosed in a first-in-human glioblastoma trial. First-in-class mechanism. Works where nothing else does including TMZ-resistant patients. Two abstracts accepted at ASCO 2026 opening this Friday. Short float 3.62% so not a traditional squeeze but volume has been running 300-400% of average with no public catalyst. Turning Point Therapeutics had two ASCO abstracts. Bristol Myers acquired …